Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD assessed from blood in multiple myeloma may be an indicator of early response SEATTLE, Dec. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data demonstrating the expanding use of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® test in assessing minimal residual disease (MRD) in blood cancer patient care and in clinical trials.

适应治疗的研究表明，MRD评估有可能指导血癌护理的个性化。新数据表明，从多发性骨髓瘤血液中评估的MRD可能是早期反应的指标西雅图，2023年12月9日（环球通讯社）——自适应生物技术公司（纳斯达克：ADPT），一家商业阶段的生物技术公司，旨在将适应性免疫系统的遗传学转化为临床产品以诊断和治疗疾病，今天宣布了新的数据，证明自适应的基于下一代测序（NGS）的clonoSEQ®测试在评估血癌患者护理和临床试验中的最小残留病（MRD）方面的应用正在扩大。

The data are being presented in more than 30 abstracts at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California. Minimal residual disease, also known as measurable residual disease, refers to the residual malignant cells that can be present in the body after treatment at very low levels and can only be identified by highly sensitive tests.

12月9日至12日在加利福尼亚州圣地亚哥举行的美国血液学会（ASH）第65届年会上，30多篇摘要介绍了这些数据。微小残留病，也称为可测量残留病，是指在极低水平治疗后可能存在于体内的残留恶性细胞，只能通过高度敏感的测试来识别。

clonoSEQ, which is the only FDA-cleared test for MRD assessment in lymphoid malignancies, is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment. “The already-substantial body of evidence supporting clonoSEQ’s prognostic value and clinical actionability is expanding in several important ways at ASH this year,” said Susan Bobulsky, Senior Vice President, Diagnostics, Adaptive Biotechnologies.

clonoSEQ是FDA批准的唯一用于淋巴恶性肿瘤MRD评估的测试，与其他用于疾病负担评估的技术相比，它具有高度的准确性，敏感性和标准化。“支持clonoSEQ预后价值和临床可行性的大量证据今年在ASH的几个重要方面正在扩大，”适应性生物技术诊断高级副总裁苏珊·博布尔斯基（SusanBobulsky）说。

“We are pleased to see many studies presented elucidating the role of clonoSEQ MRD testing in blood – both in multiple myeloma, where blood-based testing can expand patient access to MRD insights, and in a variety of subtypes of non-Hodgkin lymphoma, s.

“我们很高兴看到许多研究阐明了clonoSEQ MRD检测在血液中的作用-无论是在多发性骨髓瘤中，基于血液的检测可以扩大患者获得MRD见解的机会，还是在各种非霍奇金淋巴瘤亚型中。